Patents Assigned to Probiodrug AG
-
Publication number: 20100021478Abstract: The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: ApplicationFiled: July 10, 2009Publication date: January 28, 2010Applicant: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
-
Publication number: 20100009337Abstract: Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes.Type: ApplicationFiled: July 2, 2009Publication date: January 14, 2010Applicant: PROBIODRUG AGInventors: Stephan Schilling, Holger Cynis, Jens-Ulrich Rahfeld, Hans-Ulrich Demuth
-
Patent number: 7625939Abstract: The present invention relates to DP IV-inhibitors of formula (1) for the treatment and/or prophylaxis of diseases of mammals including cancer and tumors, metastasis and tumor colonization; and metabolic diseases.Type: GrantFiled: May 14, 2008Date of Patent: December 1, 2009Assignee: Probiodrug AGInventors: Ulrich Heiser, Andre J. Niestroj, Ulf-Torsten Gaertner, Hans-Ulrich Demuth
-
Publication number: 20090269301Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, R1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R2 represents hydrogen; halogen; alkenyl; alkynyl; -alkenylaryl; -alkenylheteroaryl; alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; -alkylcarbocyclyl; -alkylheterocyclyl; aryl; heteroaryl; heterocyclyl; -alkylaryl; -alkyl(aryl)2, -alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl-aryl; -aryl-aryl; -heteroaryl-aryl; -heteroaryl-heteroaryl, and —C(O)R4; R3 represents halogen; alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, alkoxy, thioalkyl, —C(O)OH and —C(O)O-alkyl; aryl; heteroaryl; —C(O)R5; R4 and R5 independently repreType: ApplicationFiled: November 8, 2007Publication date: October 29, 2009Applicant: PROBIODRUG AGInventors: Michael Thormann, Michael Altmstetter, Andreas Treml, Ulrich Heiser, Mirko Buchholz, Andre J. Niestroj
-
Patent number: 7592467Abstract: The present invention relates to novel inhibitors of prolyl endopeptidase of formula (1) wherein I, A, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.Type: GrantFiled: April 7, 2006Date of Patent: September 22, 2009Assignee: Probiodrug AGInventors: Andre Johannes Niestroj, Ulrich Heiser, Hans-Ulrich Demuth, Susanne Aust
-
Publication number: 20090183267Abstract: The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.Type: ApplicationFiled: January 14, 2009Publication date: July 16, 2009Applicant: PROBIODRUG AGInventors: Stephan Schilling, Torsten Hoffmann, Hans-Ulrich Demuth
-
Publication number: 20090149394Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.Type: ApplicationFiled: July 29, 2008Publication date: June 11, 2009Applicant: PROBIODRUG AGInventors: Stephan Schilling, Torsten Hoffmann, Andre Johannes Niestroj, Hans-Ulrich Demuth, Ulrich Heiser
-
Publication number: 20090098052Abstract: A transgenic non-human animal, in particular a transgenic mouse encoding A? peptide proteins, which have been implicated in A? peptide-related diseases. Cells and cell lines comprising transgenes encoding for A? peptide. Methods and compositions for evaluating agents that affect A? peptide, for use in compositions for the treatment of A? peptide-related diseases.Type: ApplicationFiled: September 12, 2008Publication date: April 16, 2009Applicant: Probiodrug AGInventors: Stephan Schilling, Holger Cynis, Hans-Ulrich Demuth, Wolfgang Jagla, Sigrid Graubner
-
Publication number: 20090068699Abstract: An inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis, b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas, e. metabolic diseases, e.g. hypertension, f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis. Additionally disclosed are a respective diagnostic method, assay and kit.Type: ApplicationFiled: February 28, 2008Publication date: March 12, 2009Applicant: PROBIODRUG AGInventors: Stephan Schilling, Holger Cynis, Torsten Hoffmann, Hans-Ulrich Demuth
-
Publication number: 20090062203Abstract: A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.Type: ApplicationFiled: September 2, 2008Publication date: March 5, 2009Applicant: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Ants Kask, Huu Phuc Nguyen, Stephan von Hoersten, Susanne Kruber, Matthias Hoffmann
-
Publication number: 20090018087Abstract: The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.Type: ApplicationFiled: October 24, 2007Publication date: January 15, 2009Applicant: PROBIODRUG AGInventors: Stephan Schilling, Mirko Buchholz, Andre Niestroj, Ulrich Heiser, Hans-Ulrich Demuth
-
Patent number: 7462599Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.Type: GrantFiled: October 15, 2004Date of Patent: December 9, 2008Assignee: Probiodrug AGInventors: Stephan Schilling, Torsten Hoffmann, André Johannes Niestroj, Hans-Ulrich Demuth, Ulrich Heiser
-
Publication number: 20080293618Abstract: The present invention relates to DP IV-inhibitors of formula (1) for the treatment and/or prophylaxis of diseases of mammals including cancer and tumors, metastasis and tumor colonization; and metabolic diseases.Type: ApplicationFiled: May 14, 2008Publication date: November 27, 2008Applicant: PROBIODRUG AGInventors: Ulrich Heiser, Andre J. Niestroj, Ulf-Torsten Gaertner, Hans-Ulrich Demuth
-
Publication number: 20080292582Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers, stereoisomers and polymorphs thereof, wherein A, B and R? are as defined throughout the description and the claims.Type: ApplicationFiled: April 18, 2008Publication date: November 27, 2008Applicant: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, Antje Hamann
-
Publication number: 20080286231Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.Type: ApplicationFiled: April 18, 2008Publication date: November 20, 2008Applicant: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, Andre J. Niestroj, Robert Sommer
-
Publication number: 20080286810Abstract: Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.Type: ApplicationFiled: April 11, 2008Publication date: November 20, 2008Applicant: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Torsten Hoffmann, Andre Johannes Niestroj, Stephan Schilling, Ulrich Heiser
-
Publication number: 20080267912Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.Type: ApplicationFiled: April 18, 2008Publication date: October 30, 2008Applicant: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, Torsten Hoffmann, Livia Boehme
-
Publication number: 20080267911Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: R1 represents and R2, R3, R4, R5, R6, X1, X2, X3, X4, Y and Z are as defined throughout the description and the claims.Type: ApplicationFiled: April 18, 2008Publication date: October 30, 2008Applicant: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser
-
Publication number: 20080262065Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and R1, B and Y are as described throughout the description and the claims.Type: ApplicationFiled: April 18, 2008Publication date: October 23, 2008Applicant: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, Antje Harmann
-
Publication number: 20080262063Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R1, R2, R3, R4, R5, R6 and Z are as defined throughout the description and the claims.Type: ApplicationFiled: April 18, 2008Publication date: October 23, 2008Applicant: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser, Andre J. Niestroj